December 2016
-
Posted on OINDPnews on May 2, 2018. Job postings may or may not be removed from the site after the position is filled. Catalent, Morrisville, NC, USA Position Summary The role supports Catalent’s Inhalation product… Read more . . .
-
Avadel Pharmaceuticals has announced the launch of Noctiva desmopressin nasal spray for the treatment of nocturia due to nocturnal polyuria (overproduction of urine at night) in adults. Avadel acquired US and Canadian rights to Noctiva… Read more . . .
-
Smartinhaler maker Adherium has announced a collaboration with pulmonary disease management provider Vitalus Health for promotion of Adherium’s inhaler monitoring technology to COPD patients in the southwest US. In September 2017, Adherium’s SmartTouch sensor received… Read more . . .
-
Clement Clarke International has announced the availability of a new smartphone app called the Trainhaler Buddy for use with its Trainhaler device to teach patients correct inhaler use technique. The Trainhaler Buddy app uses animations… Read more . . .
-
Submit abstracts for oral and poster presentations by 13 July 2018 at https://aerosol-soc.com/abstract-submission/ Abstract guidelines can be found at https://aerosol-soc.com/assets/uploads/2018/04/DDL-Abstract-Guidelines-2018.doc Themes for DDL2018 are: Insights in respiratory medicine – New therapeutic opportunities for treating asthma,… Read more . . .
-
The US Federal Trade Commission (FTC) is requiring Impax to divest several products in order to complete a planned merger with Amneal that the companies announced in October 2017. To satisfy the FTC requirements, Impax… Read more . . .
-
Mundipharma’s k-haler breath-activated metered dose inhaler has won two platinum A’ Design Awards in the ‘Scientific Instruments, Medical Devices and Research Equipment Design’ and ‘Ease of Use and Universal Design’ categories. In October 2017, the… Read more . . .
-
MannKind Corporation has announced that FDA is no longer requiring a Risk Evaluation and Mitigation Strategy (REMS) communication plan for Afrezza inhaled insulin. Afrezza was approved in the US in June 2014, with the FDA… Read more . . .
-
According to GlaxoSmithKline and Innoviva, the FDA has approved an expanded indication for the Trelegy Ellipta fluticasone furoate/umeclidinium/vilanterol DPI, allowing the use of Trelegy Ellipta for COPD patients with airflow limitation or with acutely worsening… Read more . . .
-
A US company called Honu Xpress says that it has acquired a license for the Mystabis cannabis MDI which it claims “provides pressurized metered-doses of cannabis oil directly to the lung’s capillaries with little to… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland